Open-label Study to Assess SMT04 Pro Supplement for Adults Aged 18-70 With Irritable Bowel Syndrome IBS with Diarrhea or Mixed Subtypes

What this Trial Is About

Irritable Bowel Syndrome IBS is a common disorder affecting the bowel, causing symptoms like abdominal pain and changes in bowel habits. This condition involves a complex interaction of biological, psychological, and social factors, and it can significantly reduce quality of life. Researchers are exploring new treatments to improve symptoms and quality of life for IBS patients, focusing on the role of gut bacteria. This trial studies SMT04 Pro, a dietary supplement containing a blend of probiotics including Bifidobacteria and Streptococci strains. Participants will take 2 sachets daily for 3 months. These probiotics are thought to potentially help by altering gut bacteria and reducing symptoms related to IBS. The study is open-label, meaning all participants receive SMT04 Pro without a comparison group. Participants will be assessed for IBS symptom severity using a scoring system at the start and after 3 months of treatment. Researchers will also track changes in gastrointestinal symptoms and monitor for safety. The involvement lasts for at least 3 months, during which participants complete questionnaires and other evaluations to measure treatment effects and well-being.

Evaluate the Effect of Synbiotics in Irritable Bowel Syndrome